Immunic, Inc. (IMUX) stock
IMUXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$7.52−0.27 (-3.47%)
Close on Nov 13, 2026Market cap $102.61MP/E –Yield 0.00%
Immunic EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Immunic's EPS for the twelve months ending Sep 30, 2026 was -$3.86. For fiscal 2025 it was -$6.20. The highest annual figure on record is -$6.20 in fiscal 2025.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$6.20 | – |
| FY2024 | Dec 31, 2024 | -$10.00 | – |
| FY2023 | Dec 31, 2023 | -$21.10 | – |
| FY2022 | Dec 31, 2022 | -$37.80 | – |
| FY2021 | Dec 31, 2021 | -$39.30 | – |
| FY2020 | Dec 31, 2020 | -$28.10 | – |
| FY2019 | Dec 31, 2019 | -$45.20 | – |
| FY2018 | Dec 31, 2018 | -$136.30 | – |
| FY2017 | Dec 31, 2017 | -$655.00 | – |
| FY2016 | Dec 31, 2016 | -$655.00 | – |
| FY2015 | Dec 31, 2015 | -$1035.00 | – |
| FY2014 | Dec 31, 2014 | -$1770.00 | – |
| FY2013 | Dec 31, 2013 | -$37430.00 | – |
| FY2012 | Dec 31, 2012 | -$8945.00 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$0.99 | – |
| Q2 FY2026 | Jun 30, 2026 | -$0.80 | – |
| Q1 FY2026 | Mar 31, 2026 | -$1.08 | – |
| Q4 FY2025 | Dec 31, 2025 | -$0.99 | – |
| Q3 FY2025 | Sep 30, 2025 | -$1.32 | – |
| Q2 FY2025 | Jun 30, 2025 | -$2.03 | – |
| Q1 FY2025 | Mar 31, 2025 | -$2.51 | – |
| Q4 FY2024 | Dec 31, 2024 | -$2.50 | – |
| Q3 FY2024 | Sep 30, 2024 | -$2.40 | – |
| Q2 FY2024 | Jun 30, 2024 | -$2.10 | – |
| Q1 FY2024 | Mar 31, 2024 | -$3.00 | – |
| Q4 FY2023 | Dec 31, 2023 | -$4.84 | – |
| Q3 FY2023 | Sep 30, 2023 | -$5.10 | – |
| Q2 FY2023 | Jun 30, 2023 | -$5.40 | – |
| Q1 FY2023 | Mar 31, 2023 | -$5.80 | – |
| Q4 FY2022 | Dec 31, 2022 | -$14.74 | – |
| Q3 FY2022 | Sep 30, 2022 | -$6.90 | – |
| Q2 FY2022 | Jun 30, 2022 | -$7.20 | – |
| Q1 FY2022 | Mar 31, 2022 | -$7.40 | – |
| Q4 FY2021 | Dec 31, 2021 | -$8.10 | – |
| Q3 FY2021 | Sep 30, 2021 | -$7.60 | – |
| Q2 FY2021 | Jun 30, 2021 | -$8.20 | – |
| Q1 FY2021 | Mar 31, 2021 | -$16.30 | – |
| Q4 FY2020 | Dec 31, 2020 | -$5.30 | – |
| Q3 FY2020 | Sep 30, 2020 | -$7.00 | – |
| Q2 FY2020 | Jun 30, 2020 | -$9.00 | – |
| Q1 FY2020 | Mar 31, 2020 | -$7.90 | – |
| Q4 FY2019 | Dec 31, 2019 | -$7.50 | – |
| Q3 FY2019 | Sep 30, 2019 | -$8.20 | – |
| Q2 FY2019 | Jun 30, 2019 | -$15.20 | – |
| Q1 FY2019 | Mar 31, 2019 | -$50.90 | – |
| Q4 FY2018 | Dec 31, 2018 | -$56.80 | – |
| Q3 FY2018 | Sep 30, 2018 | -$21.20 | – |
| Q2 FY2018 | Jun 30, 2018 | -$31.50 | – |
| Q1 FY2018 | Mar 31, 2018 | -$26.70 | – |
| Q4 FY2017 | Dec 31, 2017 | -$175.00 | – |
| Q3 FY2017 | Sep 30, 2017 | -$150.00 | – |
| Q2 FY2017 | Jun 30, 2017 | -$145.00 | – |
| Q1 FY2017 | Mar 31, 2017 | -$195.00 | – |
| Q4 FY2016 | Dec 31, 2016 | -$185.00 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?